Apellis Pharmaceuticals, Inc. 4

Stephanie Monaghan O'Brien and her spouse had all Apellis common stock and in-the-money stock options cashed out or converted into cash-plus-CVR consideration pursuant to Biogen’s merger, leaving them with no remaining Apellis equity holdings.

On May 14, 2026, in connection with the closing of Biogen Inc.’s acquisition of Apellis Pharmaceuticals, Inc., Stephanie Monaghan O'Brien and her spouse had all of their Apellis common stock and stock options effectively cashed out or cancelled pursuant to the Merger Agreement. Shares of common stock (including 25,666 directly held and 5,750 held indirectly by her spouse, plus several smaller directly held positions) were converted into the right to receive $41.00 in cash per share plus one non-transferable contingent value right (CVR) per share, with potential additional payments of up to $4.00 per share upon achieving specified milestones. In addition, multiple tranches of vested stock options with exercise prices below $41.00 (covering 175,80 + 121,894 + 14,684 + 27,600 + 11,199 + 8,554 + 7,441 + 27,600 + 5,748 shares) were cancelled and converted into the right to receive cash equal to the spread between $41.00 and the respective exercise prices, plus one CVR per underlying share, while any options with exercise prices at or above $45.00 were cancelled without consideration. Following these transactions, Form 4 indicates zero direct or indirect ownership of Apellis common stock or options, as Apellis became a wholly owned subsidiary of Biogen.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224592

Alert Tier

6